Characterization of Anti-HCV Antibodies in IL-10-Treated Patients - Wikidata - awgldk - TriplyDB

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

http://www.wikidata.org/entity/Q34296870

about

The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance.Inflamed gut mucosa: downstream of interleukin-10.

P2860

Q36794134-5403C6D3-BAE3-4FAC-B490-1896007F9A67 Q37883443-1D91FB80-8914-4FA5-9D7E-D4B1B206192A

P2860

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

http://www.wikidata.org/entity/Q34296870

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@ast

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@en

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@nl

type

label

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@ast

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@en

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@nl

prefLabel

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@ast

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@en

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@nl

P1433

Q34296870-8E269646-CBB9-4A0B-BB87-538216C155CE

P1476

Q34296870-D9B1CF1E-F730-4270-ACE4-D0389489E4CC

P2093

Q34296870-1E4996CB-C47B-4C83-80DE-D6FFBDAD3380

Q34296870-282F900F-91A8-4BE7-A161-B022229481DB

Q34296870-350590FD-96B7-4D3C-B3F0-5F20431679D1

Q34296870-398DDBE6-5217-41E1-A1C9-1D15D6668F39

Q34296870-5FFD5FC9-9D51-47F5-9A57-0DBD26A1E332

Q34296870-83068D6C-FCF0-42D1-93B3-690774FDD774

Q34296870-8549B26C-B31E-4217-B961-3A36683F5851

Q34296870-AAAB53AB-0429-4A4D-956C-BA151EEC6732

Q34296870-B19DAA4C-92A2-4A41-A46A-A175E375C8A4

Q34296870-C1B7CEC9-BD03-47EC-B2A6-982446E7AED8

P2860

Q34296870-0E557A11-14F6-473A-ACFD-B85F4A5DAA89

Q34296870-19768A4F-9C97-48BA-8721-4B591DF4627E

Q34296870-2C344B6A-9B66-4D49-8EF8-713D369500CB

Q34296870-2D401556-6EB3-405A-8D94-6DECD37DB432

Q34296870-2EE8A81B-AE88-4F3E-B445-2CFA5EAC687B

Q34296870-3686B28D-F370-4576-8744-423CE7FB4168

Q34296870-36FD8EAB-2661-4CE5-B512-5FDF6F1E3CB7

Q34296870-395D87B4-CD76-43C9-8153-AAB36B7FCC7E

Q34296870-4015E0D2-CC70-4422-BBB5-1F16DA22888A

Q34296870-44A9D656-D982-4CE6-9614-24E4DDA4B77C

P304

Q34296870-4DDBE264-7CB1-49EA-87EA-8EDD813E0656

P31

Q34296870-E0FE27E1-1ECE-46E4-8CDC-95ADBEB409C9

P356

Q34296870-A5F54CDD-B92A-4B8B-B96E-76A11DAC3F68

P433

Q34296870-CE02A86F-8683-435E-A910-0D96524C3E99

P478

Q34296870-27AEC8DD-70F5-488A-B43A-80DEE39F770E

P577

Q34296870-70B1AF1F-4B4F-4B4D-800F-C4149F277950

P5875

Q34296870-25777E20-97C8-4F9E-B42A-EEF1EEDAEE97

P698

Q34296870-76745588-46FA-487E-B95E-DD7EC50F2979

P932

Q34296870-BA31EBA6-A705-4DA7-B342-B2DD1632DF44

P356

P1433

Viral Immunology

P1476

Characterization of Anti-HCV Antibodies in IL-10-Treated Patients

@en

P2093

Chen Liu

http://www.w3.org/2001/XMLSchema#string

David R Nelson

http://www.w3.org/2001/XMLSchema#string

Erika A Eksioglu

http://www.w3.org/2001/XMLSchema#string

Graham Jones

http://www.w3.org/2001/XMLSchema#string

Haizhen Zhu

http://www.w3.org/2001/XMLSchema#string

Hui-Jia Dong

http://www.w3.org/2001/XMLSchema#string

Jennifer Bess

http://www.w3.org/2001/XMLSchema#string

Jennifer Dettloff

http://www.w3.org/2001/XMLSchema#string

Parinda Dangmeon

http://www.w3.org/2001/XMLSchema#string

Roberto Firpi

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of hepatitis C virus to CD81

Interleukin-10 and the interleukin-10 receptor

Structure-function analysis of hepatitis C virus envelope-CD81 binding

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies

P304

359-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/VIM.2009.0095

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45658794

http://www.w3.org/2001/XMLSchema#string

P698

20712480

http://www.w3.org/2001/XMLSchema#string

P932

2978060

http://www.w3.org/2001/XMLSchema#string